Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia

Scandinavian Journal of Urology and Nephrology

Volumn 30, Issue 5, 1996, Pages 379-385

  Okada, Hiroshi ^a   Kawaida, Noriyuki ^a   Ogawa, Takayoshi ^a   Arakawa, Soichi ^a   Matsumoto, Osamu ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Anti androgen; Benign prostatic hyperplasia; Combination therapy; 1 adrenoceptor blocker

Indexed keywords

ANTIANDROGEN; CHLORMADINONE; TAMSULOSIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THERAPY;

EID: 0029849606     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365599609181314     Document Type: Article

References (16)

1. Boyarsky S, Jones G, Paulson DF, Prout GR. A new look at bladder neck obstruction by Food and Drug Administration regulators: guide lines for investigation of benign prostatic hypertrophy. Trans Am Genito-Urin Surg 1979; 68: 29-31.
2. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-263.
3. Chapple CR, Christmas TJ, Milroy EJG. A twelve-week placebo controlled study of prazosin in the treatment of prostatic obstruction. Urol Int 1990; 45: 47-55.
4. Gormley GJ, Stoner E, Bruskewitzs RG, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-1191.
5. Gup DI, Shapiro E, Baumann M, Lepor H. Autonomic receptors in human prostate adenomas. J Urol 1990; 143: 179-185.
6. Jimenez Cruz JF. The role of alpha-adrenergic blockers in the treatment of prostatic hypertrophy. Drugs of Today 1993; 29: 343-349.
7. Jonler M. Riehmann, Bruskewitz R. Benign prostatic hyperplasia: current pharmacological treatment. Drugs 1994; 47: 66-81.
8. Kawabe K, Niijima T. Use of an alpha blocker, YM-12617, in micturition difficulty. Urol Int 1987; 42: 280-284.
9. Kunishima Y, Kawabe K, Niijima T, Honda K, Tanaka T. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra. J Urol 1985; 134: 396-398.
10. Lepor H. Role of α-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate 1990; (Suppl 3): 75-84.
11. Lepor H, Gup DI, Baumann M, Shapiro E. Comparison of alpha 1 adrenoceptors in the prostate adenoma and prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. Br J Urol 1991; 67: 493-498.
12. MacGrath JC, Grown CM, Wilson VG. α-Adrenoceptors, in receptor data for biological experiments: in Doods, et al. (eds.): A guide to drug selectivity. New York: Ellis Horwood, 1991, pp 13-18.
13. Price DT, Schwin JW, Lomasney JW, Allen LP, Caron MG, Lefkowittz RJ. Identification, quantification, and localization of mRNA for the three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-551.
14. Ruutu ML, Hansson E, Juusela HE, et al. Efficacy and side-effects of prazosin as a systemic treatment of benign prostatic obstruction. Scand J Urol Nephrol 1991; 25: 15-19.
15. Shida K. Fundamental and clinical study of anti-androgens. Androgen-dependency of prostatic tumors and clinical application of anti-androgens. Asian Med J 1981; 24: 747-777.
16. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram: II. Clinical correlation. J Urol 1980; 123: 208-210.